Ms. Jallal brings extensive CEO, healthcare industry and finance experience to the Board gained through her current CEO position at a multinational, biotechnology company, as well as several former leadership positions at biopharmaceutical companies, including as President at a biologic research and development subsidiary of a large public company. Her current CEO position and other former executive positions also provide her with regulatory and public policy experience due to the highly-regulated nature of the biopharmaceutical and biotechnology industries. Professional and Other Experience: Immunocore Holdings plc, a T-cell receptor biotechnology company, CEO (since 2019) AstraZeneca PLC ( AstraZeneca ), a pharmaceutical and biopharmaceutical business, Executive Vice President (2013-2019) MedImmune, a biotechnology business and a subsidiary of AstraZeneca, President (2013-2019), Executive Vice President, Research and Development (2010-2013) and various other research and development positions (2006-2010) Other Public Board Service: Immunocore Holdings plc, Director (since 2019) ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company (publicly traded beginning 2024), Director (2022-2024) Guardant Health, Inc., a precision oncology company, Director (2019-2022) Age: 64 Director Since: 2018 Committees: Compensation and Talent Governance (Chair) Skills, Experiences and Attributes: CEO COO/Executive Leadership Finance/Capital Markets Healthcare Industry Regulatory/Public Policy Diversity Education: M.S. and Ph.D., I Universite De Paris VI; Fellow, Max Planck Institute of Biochemistry